CATALOGO DEI PRODOTTI DELLA RICERCA

FATTOVICH, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.926
EU - Europa 9.137
AS - Asia 6.056
SA - Sud America 748
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 9
Totale 27.945
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.855
GB - Regno Unito 3.666
SG - Singapore 2.799
CN - Cina 2.353
FR - Francia 1.081
DE - Germania 798
IE - Irlanda 781
RU - Federazione Russa 766
BR - Brasile 686
SE - Svezia 686
HK - Hong Kong 561
FI - Finlandia 522
IT - Italia 497
UA - Ucraina 169
TR - Turchia 89
KR - Corea 78
CA - Canada 47
PL - Polonia 28
AT - Austria 25
BE - Belgio 23
BD - Bangladesh 22
IN - India 22
AR - Argentina 20
JP - Giappone 20
NL - Olanda 17
ZA - Sudafrica 15
ES - Italia 14
EC - Ecuador 12
MX - Messico 11
TN - Tunisia 11
UZ - Uzbekistan 11
IQ - Iraq 10
AZ - Azerbaigian 9
CL - Cile 9
EU - Europa 9
PK - Pakistan 9
MA - Marocco 8
PE - Perù 8
LT - Lituania 7
PS - Palestinian Territory 7
VN - Vietnam 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
BG - Bulgaria 6
CZ - Repubblica Ceca 6
EG - Egitto 6
RO - Romania 6
GR - Grecia 5
ID - Indonesia 5
KE - Kenya 5
MD - Moldavia 5
PT - Portogallo 5
SA - Arabia Saudita 5
CH - Svizzera 4
DZ - Algeria 4
GA - Gabon 4
HU - Ungheria 4
IR - Iran 4
KG - Kirghizistan 4
NO - Norvegia 4
PY - Paraguay 4
TH - Thailandia 4
VE - Venezuela 4
A2 - ???statistics.table.value.countryCode.A2??? 3
IL - Israele 3
JO - Giordania 3
KZ - Kazakistan 3
LB - Libano 3
NZ - Nuova Zelanda 3
PA - Panama 3
UY - Uruguay 3
BH - Bahrain 2
BN - Brunei Darussalam 2
CO - Colombia 2
EE - Estonia 2
GE - Georgia 2
HR - Croazia 2
JM - Giamaica 2
LV - Lettonia 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BT - Bhutan 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
HN - Honduras 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MM - Myanmar 1
MY - Malesia 1
NI - Nicaragua 1
Totale 27.940
Salva come PNG Salva come JPEG
Città #
Southend 2.941
Jacksonville 2.515
Singapore 1.866
Woodbridge 1.525
Chandler 1.414
Ann Arbor 934
Houston 825
Dublin 781
Ashburn 777
Hong Kong 556
Wilmington 418
Lawrence 371
Princeton 371
Lancaster 356
Nanjing 301
Jinan 271
Sindelfingen 262
Shenyang 218
Beijing 200
New York 179
Kent 149
The Dalles 149
Hebei 145
Changsha 116
Tianjin 106
Zhengzhou 99
Boardman 97
Haikou 91
Nanchang 90
Milan 85
Helsinki 78
Verona 74
Taizhou 73
Jiaxing 71
Ningbo 68
Hangzhou 64
Taiyuan 61
Guangzhou 60
Los Angeles 52
Norwalk 50
São Paulo 48
Washington 46
Moscow 45
Dallas 43
Falls Church 42
Seattle 42
Lanzhou 40
Santa Clara 35
Chicago 28
Philadelphia 27
Nuremberg 26
San Francisco 22
Fuzhou 21
Rio de Janeiro 21
Brussels 20
Toronto 20
Auburn Hills 18
Belo Horizonte 17
Tokyo 16
Brooklyn 15
Rome 15
Turku 15
Dearborn 13
Fairfield 13
Warsaw 13
Boston 12
Brasília 12
Council Bluffs 12
Goiânia 12
Mehlingen 11
Redwood City 11
Seoul 11
Stockholm 11
Tashkent 11
Edinburgh 10
Porto Alegre 10
Tappahannock 10
Baku 9
Charlotte 9
Curitiba 9
Munich 9
San Mateo 9
Vienna 9
Amsterdam 8
Campinas 8
Frankfurt am Main 8
Johannesburg 8
Phoenix 8
Qingdao 8
Serra 8
Bucheon-si 7
Clearwater 7
Düsseldorf 7
Lima 7
Madrid 7
Paris 7
Radomsko 7
Salvador 7
San Diego 7
Atlanta 6
Totale 19.832
Salva come PNG Salva come JPEG
Nome #
Metodo radioimmunologico ed elettrosineresi nello studio dell'antigene Australia (HBAg) e dell'anticorpo (HBAc). Risultati comparativi 283
Accuracy of ultrasound in the detection of liver fibrosis in chronic viral hepatitis. 176
La regressione della cirrosi epatica: non più un mito. 156
Progression to cirrhosis and mortality of chronic hepatiita type B: a cohort study with 25 years follow-up in Italy. 131
A 25 years longitudina study of hepatitis B e antigen positive chornic hepatitis B in italian patients 129
Protease inhibitors-based therapy induces acquired spherocytic-like anemia and ineffective erythropoiesis in chronic HCV patients 127
TLR4 rs4986790 A>G genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis C. 126
Endogenously produced TNF-α contributes to the expression of CXCL10/IP-10 in IFN-λ3-activated plasmacytoid dendritic cells 124
Autoantibodies during alpha-interferon therapy for chronic hepatitis B 123
Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. 123
The homestasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. 120
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 120
Malattie autoimmuni del fegato 118
Hepatitis C virus genotype and prognosis of compensated cirrhosis type C 116
A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. 115
A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. 114
Suppressor cell function in chronic active hepatitis 114
Effect of hepatitis B and C virus infection on the natural history of compensated cirrhosis: a cohort study of 297 patients. 113
HCV gentotype 3 and circulating squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV infected patients. 112
Consensus interferon (CIFN) in combination with ribavirin (RBV) for naive patients with chronic hepatitis C: a multicenter study 110
A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients nonresponders to interferon alone. 110
Interleukin-28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C under real-life conditions 110
Hepcidin suppression relative to iron status in patients with chronic Hepatitits C 110
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C 109
A long term study of hepatitis G virus coinfection in chronic hepatitis B 107
[Infection due to hepatitis B virus and host immune response] 106
Natural history of hepatitis B e antigen positive chronic hepatitis B in italian patients: a 25 years longitudinal study 105
PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia. 105
Interaction between vitamin D binding protein polymorphisms and vitamin D levels in the prediction of antiviral response in chronic hepatitis C. 105
Membrane oxidative damage causes hemolitic anemia during ribavirin therapy for chronic hepatitis C 104
Role of membrane oxidative damage in the pathogenesis of hemolitic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection 104
Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease 103
Influence of hepatitis delta virus infection on clinical outcome of compensated cirrhosis type B 103
A controlled trial of lymphoblastoid interferon for chronic anti-HBe/HBV-DNA positive hepatitis 101
Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays 100
Efficacy of prolonged high dose of interferon (IFN) plus ribavirin in young genotype 1/4 patients with chronic hepatitis C not responding to IFN alone 100
Genetic polymorphysms of vitamin d pathway predict antiviral treatment outcome in slow responder naive patients with chronic hepatitis C 100
A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. 99
Long-term outcome of chronic hepatitis B in caucasian patients: mortality after 25 years 99
Morbidity and mortality in compensated cirrhosis type C: relationship to interferon alpha therapy 98
Natural history of chronic hepatitis B 98
Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) Imaging for the Diagnosis of Cirrhosis during Liver Ultrasonography 98
Efficacy and safety of consensus interferon (CIFN) plus ribavirin (RBV) for naive patients with chronic hepatitis C (CHC): final report of a pilot study 98
Heteroimmune and autoimmune reactions to liver cell surface antigens in the pathogenesis of acute and chronic hepatitis 97
Clinical and virological profiles in patients with multiple hepatitis virus infections. 97
Incidenza e fattori di rischio di epatocarcinoma. 97
Host genetics regulates liver fibrosis progression in patients with chronic hepatitis C (CHC) 97
Hepatitis C virus genotype and risk of hepatocellular carcinoma in compensated cirrhosis type C 96
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C. 96
T and K cell function in acute and chronic hepatitis 96
Hepatocellularcarcinoma in cirrhosis: incidence and risk factors. 96
Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis 95
Influence of GB virus-C/Hepatitis G Virus infection on the long term course of chronic hepatitis B 95
Natural course and prognostic factors of hepatitis B. 95
Insulin resistance is not a relevant predictor of sustained virologic response in chronic hepatitis C patients: results from the Italian hepatitis C cohort study (ITAHECS) collaborative group 95
Interferon (IFN) induction followed by prolonged high dose IFN in combination with ribavirin (RBV) for relapsers HCV patients: a randomized controlled multicenter trial 95
TLR4 rs4986790 A>G . genetic polymorphisms predict liver fibrosis severity in Caucasian patients with chronic hepatitis B. 95
Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP) 94
Long term outcome in HBeAg positive cirrhosis treated with interferon alpha: relation between ALT normalization and survival 94
Comparison of morbidity and mortality in HBsAg positive cirrhosis with or without hepatitis delta virus superinfection 94
Hepatitis C virus genotype and clinical outcome of compensated cirrhosis type C 94
A multicenter prospective observational study to evaluate factors influencing efficacy, tolerance and compliance to antiviral treatment with interferon and ribavirin in daily clinical practice 94
Final report of a consensus interferon (CIFN) plus ribavirin (RBV) study for chronic hepatitis C (CHC) 94
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 94
Natural history of hepatitis B and prognostic factors of disease progression 93
Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients 92
Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay 92
Hepatitis C and cirrhosis 92
Natural history of HBV and HDV infection and liver disease 92
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. 92
Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study. 92
Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage 92
A survey of clinical toxicity of alfa interferon in 11.241 patients with chronic viral hepatitis 92
Cellular immunity to the hepatitis B virion in acute and chronic infection 92
A survey of clinical toxicity of alfa interferon in chronic viral hepatitis 92
Carriage of the EGF RS4444903 A>G functional polimorphism associates with disease progression in chronic HBV infection. 92
Antibody dependent cellular cytotoxicity (ADCC) in acute hepatitis B and in chronic active hepatitis 91
A multicenter randomized double-blind placebo-controlled trial of interleukin-2 in chronic hepatitis B 91
Serum levels of soluble CD30 in chronic hepatitis type B 91
Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B 90
Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. 90
Effects of interferon plus ribavirin treatment on NF-kB, TGF-b1 and metalloproteinase activity in patients with chronic hepatits C: an in vivo immunohistochemical study 90
Natural history of hepatitis B virus infection and disease 90
A randomized study comparing 48 and 96 weeks peginterferon alfa-2a therapy in genotype D HBeAg negative chronic hepatitis B. 90
IL28B genotype, differential expression of intrahepatis interferon-stimulated genes and response to PEG-IFN and ribavirin therapy in an Italian prospective cohort of genotype 1 hepatitis C patients in “real life”. 90
Natural history of chronic hepatitis B virus and Hepatitis delta virus infection and disease 89
How to predictic the outcome of chronic hepatitis B 89
Reduced serum hepcidin levels in patients with chronic hepatitis C 89
Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C 89
Antifibrogenic effect of combination interferon plus ribavirin treatment in patients with chronic hepatitis C 89
Effectiveness of interferon alfa on the clinical course of caucasian patients with viral compensated cirrhosis 89
Serum HBsAg loss in compensated cirrhosis B: relation to interferon alpha therapy and liver disease prognosis 89
Gestione delle infezioni da virus epatite B secondo le linee guida nazionali ed internazionali. 89
Suppressor cell activity in viral and non-viral chronic active hepatitis 88
Chronic persistent hepatitis type B can be a progressive disease when associated with sustained virus replication. 88
Delayed clearance of serum HBAg in compensated cirrhosis B:relation to interferon alpha therapy and disease prognosis 88
Survival and prognostic indicators in cryptogenic compensated cirrhosis: a multicenter study 88
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily clinical parameters. 88
Effectiveness of interferon alfa in caucasian patients with viral compensated cirrhosis 87
Randomized controlled trial of lymphoblastoid interferon alfa in patients with chronic hepatitis B who lacked hepatitis B e antigen. 87
Totale 10.266
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.872
article - articoli 41.213
book - libri 0
conference - conferenze 44.930
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 8.729
Totale 189.744
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020283 0 0 0 0 0 0 0 0 0 0 0 283
2020/20212.964 160 719 180 309 367 260 16 359 152 11 356 75
2021/20222.414 148 544 11 39 295 76 110 174 172 75 263 507
2022/20234.650 434 301 540 931 438 1.052 34 288 451 22 114 45
2023/20242.363 102 186 166 361 398 301 62 114 4 33 456 180
2024/20255.893 396 508 45 911 387 83 194 264 1.044 403 422 1.236
Totale 28.025